Compare DC & ASMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DC | ASMB |
|---|---|---|
| Founded | 2017 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 620.7M | 499.8M |
| IPO Year | N/A | 2010 |
| Metric | DC | ASMB |
|---|---|---|
| Price | $6.63 | $27.46 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | $9.38 | ★ $43.40 |
| AVG Volume (30 Days) | ★ 1.5M | 111.3K |
| Earning Date | 11-13-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $37,191,000.00 |
| Revenue This Year | N/A | $33.33 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 31.30 |
| 52 Week Low | $2.21 | $7.75 |
| 52 Week High | $7.25 | $39.71 |
| Indicator | DC | ASMB |
|---|---|---|
| Relative Strength Index (RSI) | 61.96 | 36.77 |
| Support Level | $6.21 | $26.93 |
| Resistance Level | $7.25 | $32.31 |
| Average True Range (ATR) | 0.39 | 1.69 |
| MACD | 0.03 | -0.30 |
| Stochastic Oscillator | 64.89 | 20.50 |
Dakota Gold Corp is a gold exploration and development company with a specific focus on revitalizing the Homestake District in Lead, South Dakota. Dakota Gold has high-caliber gold mineral properties covering over 48 thousand acres surrounding the historic Homestake Mine. Company project includes Richmond Hill Project.
Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.